We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
-$310M
Cap. Flow %
-11.3%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 8.27%
2 Energy 1.27%
3 Technology 0.21%
4 Communication Services 0.15%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OEF icon
1
PUT
iShares S&P 100 ETF
OEF
$19.8B
$224M 8.17%
18,137
-1,208
-6% -$112K
LLY icon
2
CALL
Eli Lilly
LLY
$1.09T
$223M 8.12%
26,671
+16,710
+168% +$1.27M
SPY icon
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$206M 7.51%
10,000
+2,559
+34% +$538K
BIIB icon
4
CALL
Biogen
BIIB
$30.4B
$176M 6.4%
4,345
+1,243
+40% +$499K
GILD icon
5
CALL
Gilead Sciences
GILD
$167B
$151M 5.5%
12,877
+2,910
+29% +$318K
MRK icon
6
CALL
Merck
MRK
$326B
$56.9M 2.08%
10,480
-7,533
-42% -$422K
ABBV icon
7
CALL
AbbVie
ABBV
$465B
$53.9M 1.96%
8,015
-2,292
-22% -$150K
BMRN icon
8
CALL
BioMarin Pharmaceuticals
BMRN
$12B
$51.9M 1.89%
3,796
+1,635
+76% +$203K
ALNY icon
9
CALL
Alnylam Pharmaceuticals
ALNY
$38.5B
$49.8M 1.82%
4,157
+908
+28% +$109K
REGN icon
10
PUT
Regeneron Pharmaceuticals
REGN
$72.9B
$46.3M 1.69%
907
+328
+57% +$160K
BIIB icon
11
PUT
Biogen
BIIB
$30.4B
$44.8M 1.64%
1,110
+596
+116% +$239K
XLV icon
12
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.2B
$44.6M 1.63%
+5,998
New +$445K
THC icon
13
PUT
Tenet Healthcare
THC
$22.6B
$35.6M 1.3%
6,148
+396
+7% +$20.2K
GILD icon
14
PUT
Gilead Sciences
GILD
$167B
$34.4M 1.25%
2,935
+1,103
+60% +$121K
TEVA icon
15
PUT
Teva Pharmaceuticals
TEVA
$36.9B
$30.8M 1.12%
5,210
+3,695
+244% +$228K
MRK icon
16
PUT
Merck
MRK
$326B
$29.8M 1.09%
5,485
-760
-12% -$42.6K
TLT icon
17
iShares 20+ Year Treasury Bond ETF
TLT
$43.1B
$28.9M 1.05%
246,000
+190,680
+345% +$23.4M
GWPH
18
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$25.3M 0.92%
2,062
+139
+7% +$15.8K
ABBV icon
19
PUT
AbbVie
ABBV
$465B
$24.9M 0.91%
3,704
+1,820
+97% +$119K
XOM icon
20
PUT
ExxonMobil
XOM
$634B
$24.4M 0.89%
+2,933
New +$252K
BLUE
21
CALL
DELISTED
bluebird bio
BLUE
$24.1M 0.88%
110
-121
-52% -$246K
BMRN icon
22
PUT
BioMarin Pharmaceuticals
BMRN
$12B
$22.6M 0.82%
1,652
+1,143
+225% +$142K
VTRS icon
23
PUT
Viatris
VTRS
$20.8B
$22.1M 0.81%
3,256
+256
+9% +$18.1K
MBLY
24
PUT
DELISTED
Mobileye N.V.
MBLY
$21.9M 0.8%
4,122
-1,514
-27% -$71.7K
SRPT icon
25
CALL
Sarepta Therapeutics
SRPT
$1.63B
$20.5M 0.75%
6,723
-544
-7% -$11.1K
1
2 3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management withdrew a net $310M in Q2 2015, closing 88 positions and reducing 80 holdings. Its most notable exit was Allergan plc, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in ExxonMobil worth $14.8M.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.